Itraconazole
Triazole and Tetrazole Derivatives
Sold as SPORANOX - PULSE
- Drug class
- Triazole and Tetrazole Derivatives
- Availability
- See label
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 12
Overview
Itraconazole is an active pharmaceutical ingredient in the Triazole and Tetrazole Derivatives group (J02AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 9 | May 15, 2026 |
| CA Canada | Health Canada | 3 | March 18, 2026 |
GBUnited Kingdom· MHRA
9 products
Uses
1. Vulvovaginal candidosis, 2. Oropharyngeal candidosis, 3. g. tinea pedis, tinea cruris, tinea corporis, tinea manuum, 4. Pityriasis versicolor, 5. Onychomycosis caused by dermatophytes and/or yeasts, 6. The treatment of histoplasmosis, 7.
Itraconazole capsules is indicated in the following systematic fungal conditions when first-line systemic anti-fungal therapy is inappropriate or has proved ineffective. This may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.
- Treatment of cryptococcosis (including cryptococcal meningitis): in immunocompromised patients with cryptococcosis and in all patients with cryptococcosis of the central nervous system. - Treatment of aspergillosis and candidosis.
- Maintenance therapy for penicilliosis and histoplasmosis only in AIDS patients. - Maintenance therapy of cryptococcal meningitis only in AIDS patients when standard therapy is considered inappropriate. Itraconazole capsules are also indicated for prophylaxis of fungal infections in immunocompromised patients with severe neutropenia when standard therapy is considered inappropriate.
CACanada· Health Canada
3 products
Uses
MINT-ITRACONAZOLE (itraconazole) capsules are indicated for: • the treatment of the following systemic fungal infections in normal, predisposed or immunocompromised patients: 1. Invasive and non-invasive pulmonary aspergillosis. 2. Oral and/or esophageal candidiasis.
3. Chronic pulmonary histoplasmosis. 4. Cutaneous and lymphatic sporotrichosis. 5. Paracoccidioidomycosis. 6. (formerly chromomycosis) 7. Blastomycosis. The type of organism responsible for the infection should be isolated and identified and other relevant laboratory studies (wet mount, histopathology, serology) should be undertaken as appropriate to confirm diagnosis.
Therapy may be initiated prior to obtaining these results when clinically warranted; however, once these results become available, antifungal therapy should be adjusted accordingly. • the treatment of the following topical fungal infections in normal, predisposed or immunocompromised patients: 8.
Drug interactions
Known interactions involving Itraconazole. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 576. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL200750900 · revised May 15, 2026
- [2]Health Canada (DPD) · 02462559 · revised November 14, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.